Endo ((Pancreatic Hormones, Antidiabetic Drugs,and Glucagon) Flashcards Preview

P Pha T > Endo ((Pancreatic Hormones, Antidiabetic Drugs,and Glucagon) > Flashcards

Flashcards in Endo ((Pancreatic Hormones, Antidiabetic Drugs,and Glucagon) Deck (7):
1

Insulin secretagogues
- stimulate the release of endogenous insulin by promoting closure of __________ channels in the pancreatic beta-cell membrane

1st-generation sulfonylureas
- tolbutamide, tolazamide, chlorpropamide

2nd-generation sulfonylureas (mga G)
- glipizide, glimepiride, glyburide, glibenclamide, gliclazide

Meglitinides
- repaglinide, __________ (may be used in CKD patients), mitiglinide

Insulin secretagogues
- stimulate the release of endogenous insulin by promoting closure of potassium channels in the pancreatic beta-cell membrane

1st-generation sulfonylureas
- tolbutamide, tolazamide, chlorpropamide

2nd-generation sulfonylureas
- glipizide, glimepiride, glyburide, glibenclamide, gliclazide

Meglitinides
- repaglinide, nateglinide (may be used in CKD patients), mitiglinide

2

Insulin sensitizers -- ___________
- reduces fasting and postprandial glucose levels
- inhibits hepatic and renal gluconeogenesis
- stimulates glucose uptake mad glycolysis in peripheral tissues
- slows glucose absorption from the GI tract
- reduces plasma glucagon levels
- reduces the risk of diabetes in high-risk patients

___________
- DOC for obese patients
- contraindicated inpatients with renal disease, alcoholism, hepatic disease or conditions predisposing to tissue anoxia

Insulin sensitizers -- Biguanides
- reduces fasting and postprandial glucose levels
- inhibits hepatic and renal gluconeogenesis
- stimulates glucose uptake mad glycolysis in peripheral tissues
- slows glucose absorption from the GI tract
- reduces plasma glucagon levels
- reduces the risk of diabetes in high-risk patients

Metformin
- DOC for obese patients
- contraindicated inpatients with renal disease, alcoholism, hepatic disease or conditions predisposing to tissue anoxia

3

Insulin Sensitizers -- Thiazolidinediones
- increase target tissue sensitivity to insulin by activating the _________ receptor
- reduces the risk of diabetes in high-risk patients

Pioglitazone, rosiglitazone, troglitazone

Insulin Sensitizers -- Thiazolidinediones
- increase target tissue sensitivity to insulin by activating the PPAR-gamma receptor
- reduces the risk of diabetes in high-risk patients

Pioglitazone, rosiglitazone, troglitazone

4

_____________ Inhibitors
Acarbose, miglitol, voglibose

Alpha-Glucosidase Inhibitors
Acarbose, miglitol, voglibose

5

Amylin analog
Suppressed glucagon release. Delays gastric emptying time. Stimulates CNS to reduce appetite (anorectic effect)
Administered as an injectable preparation together with insulin

Pramlintide

6

Incretin modulator (GLP-1 agonist)
Augments glucose-stimulated insulin release from pancreatic beta cells.
Retards gastric emptying
Inhibits glucagon secretion
Produces satiety
Administered as an injectable preparation used in combination with metformin or a sulfonylurea

Exenatide, liraglutide

(GLP-1 agonistide)

7

Incretin modulator -- DPP-4 inhibitor
Inhibits DPP-4 that degrades GLP-1 and other incretins
Administered orally as a monotherapy or in combination with metformin

Sitagliptin, saxagliptin, linagliptin
(DPP-4 inhibitorgliptin)

Decks in P Pha T Class (62):